CORDIS
EU research results

CORDIS

English EN
Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease

Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease

Objective

6.1 million people currently live with a form of dementia in the European Union with an addition of 1.4 million new cases every year. Combination of psychological testing, brain-imaging and exclusion of other neurological disorders makes the diagnosis of Alzheimer’s disease complicated and time consuming (taking up to 20 months). A rapid, sensitive and specific immunoassay for protein markers inside blood would largely improve early diagnosis and lead to a better treatment of dementia. Homogeneous assays based on FRET from one dye labeled specific antibody (AB1) to another (AB2) within an “AB1-biomarker-AB2” immune complex are an ideal basis to meet these diagnostic requirements. As the detection of several protein markers is obligatory for a highly sensitive and specific diagnosis an optical multiplexing approach with dyes of different colors is a smart solution. Semiconductor quantum dots (QDs) are the ideal candidates due to their size-dependent absorption and emission wavelengths. Moreover, they possess unique photophysical properties that overcome conventional fluorescence dyes. In combination with lanthanide complexes (LCs), that display long luminescence lifetimes and well separated emission bands, QDs render a powerful multiplexing tool for highly sensitive diagnostics even for large immune complexes. FRET applications using QDs are to date restricted to academic research and a profound understanding of QD-based FRET is not available. For a comprehensive analysis the use of LCs is mandatory, because they are the only known donors for efficient FRET to QD acceptors. NANOGNOSTICS strives for a profound understanding of QD-based FRET, the synthetic creation of highly efficient QD immune sensors for detection of several Alzheimer-specific protein markers and the development of a modular high-throughput-screening immuno analyzer for the integration of QD-based multiplexing immunoassays into early diagnosis for improved patient outcome in dementia therapy.

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Address

Hansastrasse 27c
80686 Munchen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 448 725

Administrative Contact

Walter Krause (Mr.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 578 800

UNIVERSITAET POTSDAM

Germany

EU Contribution

€ 364 800

PHILIPPS UNIVERSITAET MARBURG

Germany

EU Contribution

€ 453 500

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

EU Contribution

€ 515 100

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 488 700

TURUN YLIOPISTO

Finland

EU Contribution

€ 373 599,80

EDINBURGH INSTRUMENTS LTD

United Kingdom

EU Contribution

€ 539 400

Arctic Photonics Oy

Finland

UNIVERSITE PARIS-SUD

France

EU Contribution

€ 274 439,20

Project information

Grant agreement ID: 242264

Status

Closed project

  • Start date

    1 October 2009

  • End date

    31 March 2013

Funded under:

FP7-HEALTH

  • Overall budget:

    € 5 281 158,66

  • EU contribution

    € 4 037 064

Coordinated by:

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany